Allelotyping in Mycosis Fungoides and Sézary Syndrome: Common Regions of Allelic Loss Identified on 9p, 10q, and 17p  by Scarisbrick, Julia J. et al.
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Allelotyping studies have been extensively used in a
wide variety of malignancies to de®ne chromosomal
regions of allelic loss and sites of putative tumor sup-
pressor genes; however, until now this technique has
not been used in cutaneous lymphoma. We have
analyzed 51 samples from patients with mycosis
fungoides and 15 with SeÂzary syndrome using
methods to detect loss of heterozygosity. Micro-
satellite markers were selected on 15 chromosomal
arms because of their proximity to either known
tumor suppressor genes or chromosomal abnorm-
alities identi®ed in previous cytogenetic studies in
cutaneous lymphoma. Allelic loss was present in 45%
of patients with mycosis fungoides and 67% with
SeÂzary syndrome. Loss of heterozygosity was found
in over 10% of patients with mycosis fungoides on
9p, 10q, 1p, and 17p and was present in 37% with
early stage (T1 and T2) and 57% with advanced
disease (T3 and T4). Allelic loss on 1p and 9p were
found in all stages of mycosis fungoides, whereas
losses on 17p and 10q were limited to advanced
disease. In SeÂzary syndrome high rates of loss of
heterozygosity were detected on 9p (46%) and 17p
(42%) with lower rates on 2p (12%), 6q (7%), and
10q (12%). There was no signi®cant difference in the
age at diagnosis or number of treatments received by
those with loss of heterozygosity and those without,
suggesting that increasing age and multiple treat-
ments do not predispose to allelic loss. These results
provide the basis for further studies de®ning more
accurately chromosomal regions of deletions and
candidate tumor suppressor genes involved in myco-
sis fungoides and SeÂzary syndrome. Key words: cuta-
neous T cell lymphoma/loss of heterozygosity/tumor
suppressor gene. J Invest Dermatol 117:663±670, 2001
M
ycosis fungoides is the most common form of
primary cutaneous T cell lymphoma (CTCL)
with an incidence of 0.36 per 105 person-years
(Weinstock and Gardstein, 1999). It is generally a
low-grade lymphoma, which typically presents
with cutaneous patches and plaques; however some patients
develop progressive disease with cutaneous tumors, erythroderma,
or visceral spread. SeÂzary syndrome is a leukemic form of CTCL
with an aggressive clinical course; it is rarer than mycosis fungoides
accounting for 2±10% of new cases of CTCL (Willemze et al, 1997;
Zackheim et al, 1999). It typically presents with lymphomatous
involvement of more than 90% of the skin (erythroderma), intense
pruritus, peripheral lymphadenopathy, atypical lymphocytes with
convoluted nuclei in the peripheral circulation (SeÂzary cells), and a
peripheral blood T cell clone as demonstrated by T cell receptor
(TCR) gene analysis studies (Russell-Jones and Whittaker, 1999).
Little is known about the molecular pathogenesis of mycosis
fungoides and unlike nodal lymphomas speci®c chromosomal
abnormalities have not been identi®ed. Cytogenetic studies in
nodal lymphomas and leukemia have been very rewarding and have
identi®ed several disease-speci®c abnormalities (Weiss et al, 1987;
Kurzrock et al, 1988; Chiou et al, 1994; Argatoff et al, 1997; Beylot-
Barry et al, 1998). Attempts to identify these well-de®ned
chromosomal abnormalities in primary cutaneous lymphoma have
not been fruitful. The t(14; 18) that characterizes nodal follicular
center cell lymphoma was found in only one of 14 cases of primary
cutaneous follicular center cell (Cerroni et al, 1994). Similarly, the
t(2;5) characteristic of nodal CD30+ large cell anaplastic lymphoma
was not found in 14 cases of primary cutaneous CD30+ large cell
anaplastic lymphoma (DeCoteau et al, 1996). These ®ndings suggest
that primary cutaneous lymphomas have a different pathogenesis
from their nodal counterparts despite similar morphologic features.
Peripheral blood cytogenetic studies in CTCL have been
ongoing since 1968 (Spiers et al, 1968). Clonal chromosomal
abnormalities have been identi®ed in 20±100% of patients with
SeÂzary syndrome and in the peripheral blood of some patients with
advanced stages of mycosis fungoides. Several cytogenetic studies in
patients with advanced CTCL have identi®ed multiple clonal
chromosomal abnormalities, most commonly involving structural
rearrangements of chromosomes 1, 2, 6, 9, 14, and 16 and
numerical abnormalities of 6, 8, 10, 11, 13, 17, and 21.
A recent study of 11 patients with CTCL identi®ed chromo-
somal loss between 1p22 and 1p36 in ®ve patients and rearrange-
ments of chromosome 2 in four patients (Thangavelu et al, 1997).
Rearrangements involving 2p were also detected in two of six
patients by Berger et al (1988) who reviewed the literature to
identify two common breakpoints on 2p; one clustering around
2p11±14 and the other around 2p23±25. Complete or partial
monosomy of chromosomes 8p, 17p, and isochromosome 17q have
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been identi®ed in CTCL (Nowell et al, 1982; Berger et al, 1988;
Thangavelu et al, 1997). Deletions of 6q have also been identi®ed in
several studies (Thangavelu et al, 1997; Nowell et al, 1982; Shapiro
et al, 1987). Rearrangements involving 9p were identi®ed in three
of six patients with CTCL by Berger et al (1988) in addition one
patient had a rearrangement involving 14q32. This locus was also
involved in a translocation in two of 23 patients with CTCL in a
previous study by Nowell et al (1986). Studies of SeÂzary syndrome
have identi®ed frequent abnormalities also involving 1p, 2p, 6q, 9,
10q, 13q, 17p, and 21 (Johnson et al, 1985; Sole et al, 1988; Limon
et al, 1995; Brito-Babpulle et al, 1997).
Most cytogenetic studies have been based on analysis of
metaphases from peripheral blood lymphocyte cultures even
though morphologic abnormalities are seldom present in the
peripheral blood of patients with MF. These multiple chromosomal
abnormalities have mainly been found in patients with advanced
stages of mycosis fungoides and are associated with a poor prognosis
(Thangavelu et al, 1997; Whang-Peng et al, 1979; Shapiro et al,
1987). Studies of skin biopsy material from patients with mycosis
fungoides have generally not been successful for a variety of
biologic and technical reasons. The growth of tumor cells from
solid tissues in culture is often poor because of a low mitotic index.
Cultures may be contaminated with keratinocytes, ®broblasts, or
reactive lymphocytes and preparations of good quality metaphases
from solid tumor can be dif®cult.
Although rearrangements of speci®c oncogenes have rarely been
found in CTCL, studies of tumor suppressor genes have been more
rewarding. Inactivation of P53 has been found in advanced mycosis
fungoides and SeÂzary syndrome (McGregor et al, 1995, 1999;
Lauritzen et al, 1995; Marks et al, 1996; Marrogi et al, 1999), which
is similar to ®ndings in nodal non-Hodgkin's lymphoma and
suggests that P53 gene mutations are associated with disease
progression in lymphoma (Gaidano et al, 1991). Abnormalities of
the P16 gene were detected in seven of nine patients with mycosis
fungoides in both early and advanced stages of disease (Navas et al
2000). In addition a further study found absent expression of the
P16 gene in ®ve of 20 patients with early stages of mycosis
fungoides (Peris et al, 1999). Germline mutations of P15 and P16
genes are found in some cases of familial melanoma (Hussussian et al,
1994) and inactivation of these genes has also been found in non-
Hodgkin's lymphoma (Gombart et al, 1995; Heyman et al, 1996).
We have performed an extensive allelotyping in order to identify
patterns of loss of heterozygosity (LOH) in both early and advanced
cutaneous stages of mycosis fungoides and SeÂzary syndrome. Allelic
loss is a common mechanism of tumor suppressor gene inactivation
and provides information on the likely involvement of such genes
in the pathogenesis of mycosis fungoides and SeÂzary syndrome.
MATERIALS AND METHODS
Sample selection Tumour DNA from lesional skin and normal
control DNA from the patients' peripheral blood mononuclear cells or
lymph nodes, was extracted according to standard procedures by
proteinase K digestion and phenol/chloroform extraction, from
individual patients with mycosis fungoides. All tumor samples were
chosen because, either southern blot or single strand conformational
polymorphism±polymerase chain reaction (PCR) based TCR gene
analysis (Whittaker et al, 1991; Fraser-Andrews et al, 2000) had
previously demonstrated a clonal population in lesional skin, which was
absent from the peripheral blood or lymph node. Furthermore, only
those samples with a large dominant clone were selected for this study: a
large dominant clone was determined by measuring the signal intensity
of the discrete band, using Image Master Scanning Densitometer
(Amersham Pharmacia, Piscataway, NJ) with Image Master Softwear
(Amersham Pharmacia) and only samples with a signal intensity of more
than 50% in the discrete band compared with the background smear
were considered to contain a large dominant clone.
These samples consisted of 51 patients with mycosis fungoides with
different cutaneous stages of disease: T1 = 14, T2 = 16, T3 = 17, and
T4 = 4, which included IA = 14, IB = 13, IIA = 3, IIB = 11, III = 1,
and IVA = 9 (Lamberg et al, 1984) and 15 patients with SeÂzary
syndrome (III = 8 and IVA = 7).
Microsatellite analysis Microsatellite analysis requires comparison
between tumor and normal DNA from individual patients. In most
patients with mycosis fungoides tumor DNA was extracted from lesional
skin and normal control DNA from either peripheral blood lymphocytes
or lymph nodes. All 15 cases with SeÂzary syndrome had a large dominant
T cell clone in peripheral blood. In three cases DNA from lymph nodes
did not demonstrate a T cell clone and these samples were used as a
normal control. In the other 12 cases with SeÂzary syndrome and three
patients with tumor stage mycosis fungoides T cell clones were detected
in skin, blood, lymph nodes, and bone marrow aspirates. In these
patients no DNA was available without a T cell clone and normal DNA
was obtained by isolating CD8+ cells from peripheral blood lymphocytes
as described below.
Prior to isolation of CD8+ cells, formalin-®xed paraf®n-embedded
histologic sections from lesional skin were immunostained using CD4
and CD8 monoclonal antibodies (Vector Laboratories, Burlingame, CA)
to con®rm that the tumor cells had a typical CD4+ CD8± phenotype
(Willemze et al, 1997).
First, lymphocytes were separated from whole blood using
Lymphoprep (N Fiemed, Norway) and centrifuged at 1400 r.p.m. for
25 min with gentle acceleration and deceleration. The lymphocytes were
then removed and washed using phosphate-buffered saline (Sigma,
Poole, U.K.) with centrifugation at 1400 r.p.m. for a further 10 min.
The lymphocyte pellet was then resuspended in phosphate-buffered
saline with 2% fetal bovine serum (Helena Technologies, Barnsley,
U.K.). Viable lymphocytes were counted using a Neubaeu hemocyt-
ometer with trypan blue dye exclusion. This manual counting method
includes all lymphocytes (both T cells (CD3+, including CD4+ and
CD8+ lymphocytes) and B cells (CD20+). A more accurate estimate of
the number of CD8+ lymphocytes was then calculated using the
percentage CD3 count and CD4/8 ratio for each sample. Cells were
stored in liquid nitrogen for future isolation of the CD8+ lymphocytes.
CD8 Dynabeads (Dynal AS, Norway) were used to isolate CD8+ cells
following the manufacturers' instructions. DNA extraction was then
performed using Genomic Prep Cells and Tissues DNA isolation kit
(Amersham Pharmacia) in accordance with manufacturers' instructions.
DNA was precipitated by ethanol and resuspended in 50 ml of water.
Tumor and normal DNA samples from patients with mycosis
fungoides were analyzed for allelic loss using oligonucleotide primers for
25 microsatellite markers from 15 chromosomal arms. In SeÂzary
syndrome 17 microsatellite markers on eight chromosomal arms were
analyzed. This more limited analysis was performed due to the limited
amount of normal DNA available for comparison in LOH studies.
Microsatellite markers were chosen with high rates of heterozygosity
(> 0.8) and were either close to chromosomal regions found to be
deleted in previous cytogenetic studies of CTCL or known tumor
suppressor genes (Table I). These included 21 dinucleotide markers:
Primer sequences were taken from the Genethon Human Linkage Map
(Gyapay et al, 1994), excluding U09579, RH70320, L11910 (EMBL,
Meyerhofstr, Germany), IFNA, p15, p16 (Heyman et al, 1996), p53
(Futreal et al, 1991), and four mononucleotide repeats: BAT 26, BAT
RII, BAT 34C4 (Zhou et al, 1997), and the G8 tract of the BAX gene
(Molenaar et al, 1998).
Primers for microsatellite markers were ampli®ed using the PCR in a
reaction mixture of 20 ml, including 20 pmol of each oligonucleotide
primer, 0.2 mM deoxyadenosine triphosphate, 0.2 mM deoxyguanosine
triphosphate, 0.2 mM deoxythymidine triphosphate (Amersham
Pharmacia), 0.03 mM deoxycytidine triphosphate, 0.1 mCi [a-33P]-
deoxycytidine triphosphate (3000 Ci per mmol), 50 ng of sample DNA,
1 3 PCR buffer, containing 1.5 mM MgCl2, 1.25 units Taq polymerase
(Amersham Pharmacia) and 1.25 units Taq antibody (Clontech,
Basingstoke, U.K.). Prior to PCR ampli®cation the mixtures were
denatured at 94°C for 5 min. Twenty-®ve to 30 cycles of PCR were
performed in a DNA Perkin Elmer, Wellesley, MA 9700 thermal cycler.
Each cycle consisted of denaturing at 94°C for 20 s, annealing at 55±
65°C (according to the Tm for each oligonucleotide primer pairs) for
20 s and extension at 72°C for 50 s with a prolonged extension of 5 min
during the ®nal cycle.
A negative control reaction containing no DNA was examined for
each PCR assay. After agarose gel electrophoresis, to assess ef®ciency of
ampli®cation, PCR products were diluted 2-fold with stop solution (95%
formamide, 20 mM ethylenediamine tetraacetic acid, 0.05% xylene
cyanol FF, and 0.05% bromophenol blue) and denatured for 10 min at
95°C before being loaded on to denaturing 6% polyacrylamide (Gibco
BRL, Gaithersburg, MO) gels containing 7 M urea (United States-
Biochemicals, Swampstott, MA) and electrophoresed using a S2 sequen-
cing gel apparatus (Gibco BRL). The gel was dried on 3 mm Whatmann
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paper and exposed to X-ray ®lm (Genetic Research Instrumentation,
Mans®eld, WI) with an intensifying screen (Appligene Oncor, Illkirch,
France) at room temperature for 48±72 h.
Determination of LOH All samples where two distinct allelic bands
were present in the normal DNA were considered to be informative.
Samples that produced a single allelic band in normal DNA or failed to
amplify for a given microsatellite marker were scored as noninformative.
The signal intensities for all informative samples were examined
visually by two independent observers without knowledge of clinical
details. LOH was scored as positive when a clear reduction in signal
intensity was detected in one of the alleles of the tumor DNA compared
with the same allele in the paired normal DNA.
Microsatellite analysis using different markers produces different allelic
banding patterns and LOH needs to be assessed in comparison with
other samples using the same marker. The number of bands representing
one allele varies markedly for different markers but is relatively constant
for each marker using different patient samples (Fig 1). Multiple allelic
bands occur due to slippage of DNA polymerase on the template
sequence, which may be marked because of the repetitive nature of the
microsatellite sequence (Newton and Graham, 1997). We attempted to
reduce this slippage by limiting the number of PCR cycles to 25 and
lowering the primer concentration. In addition a higher number of
bands are more frequently seen using 33P compared with 32P because a
sharper and ®ner banding pattern is produced (Payne, 1997). Finally, the
intensity of the upper group of bands, representing the larger allele, was
often less due to preferential PCR ampli®cation of smaller sized products
(Payne, 1997).
In instances where more than one band was present within each allele
the exact position of each allele was decided by comparing the banding
pattern in all samples analyzed with the same marker and selecting the
most consistent pattern: the two alleles were identi®ed as two groups of
bands of similar number and similar signal intensity (Fig 1). In order to
quantify signal intensities we also analyzed samples using a scanning
densitometer with Image Quant software (Amersham Pharmacia), a
reduction in signal intensity of more than 50% in one of the alleles in
the tumor DNA compared with the paired normal DNA was de®ned as
LOH. Many samples showed a reduction in signal intensity approaching
90%. Densitometry was undertaken on all samples where the reduction
in signal intensity was dif®cult to quantify visually. Where suf®cient
material was available samples showing LOH were subjected to repeat
ampli®cation and analysis.
Comparison of clinical parameters The mean age at diagnosis and
time from diagnosis were compared in those patients with and without
LOH, and analyzed for statistical signi®cance using unpaired t test, with
Satterthwaite's correction for unequal variances. Standard errors were
corrected for possible non-normality and unequal variances.
The number of treatments received prior to the sample skin biopsy
was calculated for each patient. Treatments were divided into the
following categories: psoralen + ultraviolet A, super®cial low-dose radio-
therapy, total skin electron beam therapy, interferon-a, extracorporeal
photopheresis, topical chemotherapy, single agent oral chemotherapy,
single agent intravenous chemotherapy, and multiagent intravenous
chemotherapy. The number of treatments received by those with and
without LOH were compared and tested for statistical signi®cance using
the above methods. Disease-speci®c death rates were calculated as the
number of deaths from disease per year from diagnosis. Disease-speci®c
death rates were similarly compared between these groups and also for
different stages of disease and tested for statistical signi®cance using the
Kaplan±Meier nonparametric test.
In addition the effect of possible predictors of age at diagnosis, number
of treatments received, stage of disease, and disease-speci®c death rates
were estimated using an appropriate regression test: least-squares linear
regression for age at diagnosis and number of treatments, logistic
regression for cutaneous stage (T1 and T2 or T3 and T4) and Cox's
proportional Hazards regression for time to death. In each case, estimates
with con®dence intervals were produced using robust standard errors to
correct for possible mild non-normality. Predictors considered were
advanced stage (T3 or T4), age and LOH (no LOH, LOH at one loci
only, LOH at more than one loci). In each case, unadjusted (univariate)
estimates were obtained prior to multivariate analysis.
RESULTS
Allelic loss in mycosis fungoides Examples of allelic loss are
shown in Fig 1. The microsatellite markers analyzed on each arm
and their approximate cytogenetic position is shown in Table I.
LOH was identi®ed at one or more loci (range = 1±4) in 23 of
51 patients (45%), Table II. The number of informative patients
for LOH studies and rates of loss on each of the 15 chromosomal
arms analyzed are shown in Table III. The number of patients
demonstrating LOH on each arm ranged from 0 to 9 (0±16%). The
most frequent chromosomal arms showing allelic loss were 9p in 8
of 49 patients (16%), 10q in 6 of 50 patients (12%), 1p in 5 of 51
patients (10%) and 17p, also in 5 of 51 patients (10%).
The male to female ratio was similar in those with and without
LOH; approximately 6 : 4. There was no signi®cant difference in
the mean age at diagnosis of mycosis fungoides in those with LOH
at 56 y and those without at 51 y (p = 0.16, 95% C.I. = 49±58).




loss in CTCL Candidate TSG Microsatellite markers
1p22±36 11,2, 1p22±363 P7316, P1817, TAL-118 D1S201, D1S247
2p16±21 2p14±251, 2p114, 2p215 hMSH2,hMSH619,20 BAT26, D2S123
3p22 TGF-beta receptor 221 BAT-RII
5q13,21±22,5q35 P2122,APC23 U09579, D5S346, D5S677
6q16.3±21,21±23.3 6q3±8, 6q21±239 D6S283, D6S261
9p21 94,8, 9p1 P15,P1624,25 IFNA, p15,16
10q23±24 103,5,8, 10q22±262,10±12 PTEN26, FAS27 D10S215, D10S541, D10S209
11q23 111,10 ATM47 D11S1347
12p12.3 1210,13, 12p11±132 LRP629 T68115
13q14.2±22 13q5,8,13q21±2210,11 Rb30 L11910, D13S160
14q32 14q13, 14q321,14 D14S1054
17q11.2±12 Iso17q4,7,9 BRCA131, NF132 D17S250
17p13.1 17p2,3, 17p1315 P5333±36 BAT34C, p53
19q BAX37 BAX(G8tract)
21q22.1 214,10 TIAM-138 D21S263
1Berger et al (1988). 2Limon et al (1995). 3Thangavelu et al (1997). 4Van Vloten et al (1980). 5Sole et al (1988). 6Shapiro et al (1987). 7Nowell et al (1982). 8Whang-Peng
et al (1982). 9Johnson et al (1985). 10Edelson et al (1979). 11Karenko et al (1997). 12Karenko et al (1999). 13Barbieri et al (1986). 14Nowell et al (1986). 15Brito-Babpulle et al
(1997). 16Kawano et al (1999). 17Hatta et al (1997). 18Janssen et al (1993). 19Lowsky et al (1997). 20Indraccolo et al (1999). 21Lagneaux et al (1997). 22Villuendas et al (1997).
23Baeg et al (1995). 24Gombart et al (1995). 25Heyman et al (1996). 26Nakahara et al (1998). 27Komada et al (1997). 28Takeuchi et al (1998). 29Baens et al (1999).
30Pescarmona et al (1999) 31Beckmann et al (1996). 32Bollag et al (1996). 33McGregor et al (1995). 34Lauritzen et al (1995). 35McGregor et al (1999). 36Marks et al (1996).
37Molenaar et al (1998). 38Chen et al (1995).
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There was no signi®cant difference in the mean number of
treatments received by those with LOH at 1.3 and those without at
1.74 (p = 0.30, 95% C.I. = 1.2±2.0) Table II.
The mean follow-up from diagnosis was 5.1 y in those
demonstrating LOH and 5.9 y in those without. Seven of 23
patients demonstrating LOH (30%) died from CTCL related
disease during follow-up compared with 4 of 28 patients without
LOH (14%). This equates to a disease-speci®c death rate of 0.06 per
year in those with LOH, which is 3 times higher than those
without LOH (p = 0.17), Table II. A graph showing Kaplan-
Meier survival estimates in patients with and without LOH is
shown in Fig 2.
A comparison of LOH rates with cutaneous stage of mycosis
fungoides revealed that six of 14 patients with T1 stage (43%), ®ve
of 16 patients with T2 (31%), 10 of 17 with T3 (59%), and two of
four with T4 stage disease (50%) demonstrated LOH at one or more
loci. No patients with T1 or T4 stage disease died from CTCL-
related causes during follow-up. Of the 16 patients with T2 stage
disease: one of ®ve with LOH died from disease (20%) compared
with one of 11 without (9%). This equates to a 2.5 times higher
disease-speci®c death rate in those with early stage disease showing
LOH than those of a similar stage without LOH. Of the 17 patients
with T3 stage disease: six of 10 with LOH died from disease (60%)
compared with three of seven without (43%). This equates to
disease-speci®c death rates of 0.10 and 0.08 per year, respectively.
Nodal disease was present in eight patients with mycosis
fungoides (stage IVA) all with advanced cutaneous disease (T3 or
T4), four of whom had LOH detected at one or more loci and four
without LOH. One patient had visceral disease (stage IVB) had
LOH detected on 17p only.
Comparing allelic loss on these chromosomal arms with
cutaneous stage: ®ve of 21 patients (24%) with advanced stage
(T3 or T4) had LOH on 10q compared with only one of 30 (3%)
with early stage disease (T1 or T2). Three of 21 patients (14%) with
advanced stage had LOH on 17p compared with only two of 30
(7%) with early stage disease. On 9p four of 21 patients with
advanced stage (19%) had LOH compared with four of 30 with
early stage disease (13%) and on 1p LOH was found in two of 21 of
patients with advanced stage (10%) and three of 30 with early stage
disease (10%).
LOH in less than 10% of patients was detected on 2p, 3p, 5q, 6q,
11q, 13q, 14q, and 17q. No region of loss was detected on 12p,
19q, or 21q.
Allelic loss in SeÂzary syndrome The microsatellite markers
analyzed on each chromosomal arm and their approximate
cytogenetic position are shown in Table IV. LOH was
identi®ed at one or more loci (range = 1±3) in 10 of 15 patients
(67%). The number of informative patients for markers on each
chromosomal arm varied between 11 and 15, mean 13. The
Table II. Clinical parameters in 51 patients with mycosis
fungoides and comparison of these parameter in patients
with and without loss of heterozygosity
Cohort No loss LOH
Total no. of patients (%) 51 (100) 28 (55) 23 (45)
Mean age at diagnosis (y) 50 47 53
No. of treatments prior to biopsy 1.53 1.36 1.74
Mean follow-up from diagnosis (y) 5.5 5.9 5.1
No. died of disease (%) 11 (22) 4 (14) 7 (30)
Disease-speci®c death rate per year 0.04 0.02 0.06
Figure 1. Microsatellite analysis using different markers produces different allelic banding patterns, LOH needs to be assessed in
comparison with other samples using the same marker.
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number of patients demonstrating LOH on each arm is shown in
Table IV and ranged from 0 to 6 (0±46%). High rates of allelic loss
were identi®ed on 9p and 17p: LOH on 9p was identi®ed in six of
13 patients (46%) and on 17p in ®ve of 12 patients (42%). Lower
frequencies of loss were found on 10q, 2p, and 6q: LOH on 10q
was detected in two of 14 patients (14%), on 2p in two of 14
patients (14%) and on 6q in one patient. LOH was not detected on
1p, 13q, or 17q.
The mean age at diagnosis of SeÂzary syndrome was 3 y younger
in those patients demonstrating allelic loss, at 63 y, compared with
those without LOH, at 60 y. The mean SeÂzary count was 77% in
those with LOH compared with 59% in those without. In those
samples demonstrating LOH 3 were from patients with stage III
and seven with stage IVA disease, whereas the ®ve samples that
failed to show LOH were all from patients with stage III disease.
The mean follow-up from diagnosis was 2.5 y in those demon-
strating LOH and patients had received on average two different
treatment modalities. In those without evidence of allelic loss the
follow-up period was 5.6 y and patients had received on average
three different treatments, Table V. All patients were alive on
entry to the study. Three patients died during follow-up, two
showing LOH and one without. Further analysis of survival data is
not relevant due to small numbers and a short follow-up period.
DISCUSSION
This study has identi®ed regions of allelic loss in both patients with
mycosis fungoides and SeÂzary syndrome. Losses were identi®ed in
45% with mycosis fungoides including 37% with early and 57%
with advanced cutaneous stages of disease and in 67% with SeÂzary
syndrome. Allelic loss was detected on 80% of chromosomal arms
studied but on most arms this involved low rates (< 5%) which may
represent background genomic instability. The literature suggests
that low-grade hematologic malignancies have a lower rate of LOH
than high-grade malignancies and studies frequently cite rates of
more than 10% as having probable signi®cance (Takeuchi et al,
1995a; CaveÂ et al, 1996; Hatta et al, 1998; Mori et al, 1997). In our
allelotyping study losses on 1p, 9p, 10q, and 17p were detected at
rates over 10%. In particular these losses on 9p (46%) and 17p (42%)
were more common in SeÂzary syndrome. These data suggest that
the same putative tumor suppressor genes are important in both
mycosis fungoides and SeÂzary syndrome malignancies and losses on
these chromosomal regions are very unlikely to represent back-
ground genetic instability.
Allelic loss was consistently found at lower rates in mycosis
fungoides and was more prevalent in advanced cutaneous disease.
The higher rate of loss in advanced mycosis fungoides and SeÂzary
syndrome may re¯ect the increased tumor burden in advanced
disease enabling detection of LOH and tumor samples from patients
with low tumor burden, as would be expected for patients with
early disease, may be noninformative. In order to overcome this
potential bias the purity of tumor DNA in all samples was assessed
using TCR gene rearrangement studies and only those samples
with a large dominant clonal T cell population were selected for
this study. This technique, however is only semiquantitative and
may have included some samples with a small clone that could have
given rise to false negative LOH results, particularly in the early
stages of disease where tumor burden is lower; however, the similar
rates of LOH detected in all cutaneous stages of MF (43% with T1,
31% with T2, 59% with T3 and 50% with T4 stage disease) coupled
with the high overall rate of LOH detected in this cohort (45%)
suggests that false negative results are rare.
Table III. Loss of heterozygosity on each chromosomal
arm in patients with mycosis fungoides
Chromosomal
arm




1p 51 5 (10)
2p 51 1 (2)
3p 49 2 (4)
5q 51 2 (4)
6q 51 1 (2)
9p 49 8 (16)
10q 50 6 (12)
11q 46 1 (2)
12p 51 0 (0)
13q 51 1 (2)
14q 51 2 (4)
17q 47 4 (9)
17p 51 5 (10)
19q 50 0 (0)
21q 45 0 (0)
Figure 2. Graph demonstrating Kaplan±Meier survival estimates
in patients with mycosis fungoides with and without LOH.
p = 0.17.
Table IV. Microsatellite markers and their approximate
chromosomal locations analyzed for loss of heterozygosity











2p16±21 BAT26, D2S123 14 2 (14)
6q16.3±23.3 D6S283, D6S261 15 1 (7)




13q14.2±22 L11910, D13S160 13 0 (0)
17q11.2±12 D17S250 11 0 (0)
17p13.1 BAT34C, p53 12 5 (42)
Table V. Clinical parameters in 15 patients with SeÂzary
syndrome and comparison of these parameter in patients
with and without loss of heterozygosity
Cohort No loss LOH
Total no. of patients (%) 15 (100) 5 (33) 10 (67)
Mean age at diagnosis (y) 62 60 63
No. of treatments prior to study 2 3 2
Mean follow-up from diagnosis (y) 3.5 5.6 2.5
Mean SeÂzary count at entry to study 61 59 77
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By only selecting samples with a large dominant clonal
population patients with the earliest stages of mycosis fungoides
were excluded. This may account for the high rates of loss detected
in the early stages of disease, as only those with a high tumor
burden were analyzed. LOH rates in patients with early cutaneous
stages of mycosis fungoides and a small clone may be assessed by
microdissecting tumor cells to enrich the tumor component. In
addition most patients were selected for this study in whom either
blood or lymph nodes did not show a T cell clone, which excluded
many patients with widespread disease from the study, although this
was in part overcome by extracting normal DNA from CD8+
lymphocytes.
Chromosomal losses on 10q have been identi®ed in previous
cytogenetic studies, commonly involving 10q22±26 (Edelson et al,
1979; Limon et al, 1995; Karenko et al, 1997). A recent study using
¯uorescent in situ hybridization methods (FISH), capable of
detecting chromosomal abnormalities in nondividing interphase
cells and comparative genomic hybridization, a novel technique
used to detect global losses or gains in tumor DNA compared with
normal DNA, detected chromosomal loss on 10q in four patients
with erythrodermic CTCL, with a minimal overlapping region of
10q25±26 (Karenko et al, 1999). Recent studies in other
malignancies have identi®ed chromosomal deletions involving
10q23±26, including transitional cell carcinoma (10q24.1±q24.2
and 10q26.1±26.2) (Cappellen et al, 1997) and endometrial
carcinoma (10q22.1±23 and 10q25.2±26.3) (Peiffer et al, 1995).
Deletion mapping in glioblastoma has also identi®ed frequent loss at
10q23.3, which has subsequently been associated with deletions of
the tumor suppressor gene PTEN (Wang et al, 1997). This study
identi®ed allelic loss on 10q in six of 50 patients (12%). Further
detailed microsatellite analysis in these patients revealed a minimal
overlapping region of deletion at 10q24 in 10 of 44 patients (23%),
which in some cases was associated with homozygous deletion of
the PTEN gene (Scarisbrick et al, 2000). These ®ndings suggest that
10q22±26 harbors one or more tumor suppressor genes involved in
the pathogenesis of various malignancies, including CTCL. Fine
mapping the deletion on 10q using additional microsatellite
markers increased the detection rate of LOH and the use of only
one to three markers on each chromosomal arm in this allelotyping
study may have underestimated the actual rates of allelic loss on
individual arms (Hatta et al, 1999; Scarisbrick et al, 2000).
Chromosomal loss on 17p has been identi®ed in CTCL (Limon
et al, 1995; Thangavelu et al, 1997) and a study using ¯uorescent
in situ hybridization analysis identi®ed a speci®c region of deletion
at 17p13 (Brito-Babpulle et al, 1997). We speci®cally selected
markers close to the P53 tumor suppressor gene at 17p13.1 because
overexpression has been found in high-grade CTCL (Lauritzen et al,
1995; McGregor et al, 1995) and several studies, including our
own, have identi®ed P53 gene mutations in a signi®cant proportion
of patients with advanced mycosis fungoides and SeÂzary syndrome
(Marks et al, 1996; McGregor et al, 1999) suggesting that
inactivation of the P53 gene is associated with disease progression
in CTCL. Our LOH data support these ®ndings: allelic loss on 17p
was found in 10% of patients with mycosis fungoides, and was more
prevalent in advanced cutaneous stages of disease (14%), and in 42%
of patients with SeÂzary syndrome. Immunohistochemical studies of
P53 gene expression in these patients found abnormal expression in
the majority of atypical lymphocytes from the three cases of tumor
stage disease suggesting the presence of biallelic P53 gene
abnormalities and subsequent loss of gene function. In the two
cases of early stage MF abnormal expression was only found in 5±
10% of tumor cells suggesting the presence of a subclone with
biallelic mutations (data not shown). Molecular studies looking for
P53 gene mutations were not performed to con®rm this. Intragenic
mutation, however is an alternative mechanism of P53 gene
inactivation and may be biallelic, thus the true rate of P53 gene
inactivation in mycosis fungoides may be greater than suggested by
LOH analysis.
Chromosomal rearrangements on 1p have frequently been
detected in CTCL (Berger et al, 1988; Limon et al, 1995), and a
common region of deletion has been identi®ed on 1p22±36
(Thangavelu et al, 1997). We targeted this region and found LOH
in 10% of patients with both early and advanced stage mycosis
fungoides; however no loss on 1p was found in any of the 15
patients with SeÂzary syndrome. Allelic loss on 1p31±36 has been
identi®ed in a variety of solid tumors, including colon, breast, and
ovary (Ragnarsson et al, 1999), as well as in chronic myeloid
leukemia on 1p36 (Mori et al, 1998) and T cell non-Hodgkin's
lymphoma on 1p32 (Perotti et al, 1999). Candidate tumor
suppressor genes in this region include the P73 gene (1p36),
which encodes a p53 homolog that may be inactivated in nodal
lymphomas (Kawano et al, 1999) and the P18 gene (1p32) a cyclin-
dependent kinase inhibitor, which is a homolog of the P15 and P16
genes. Absent P18 gene expression has been demonstrated in acute
T cell leukemia cell lines (Hatta et al, 1997). In addition the TAL1
gene (1p32) encodes a hemopoietic transcription factor and
deletions have been reported in T cell acute lymphoblastic
leukemias (Janssen et al, 1993). Studies of these candidate tumor
suppressor genes would be appropriate in determining their role in
the pathogenesis of mycosis fungoides and particularly in disease
initiation. In addition further LOH studies of patients with SeÂzary
syndrome may be of value in determining if loss on 1p occurs in a
subset of these patients.
Chromosomal abnormalities on 9p have previously been iden-
ti®ed in CTCL (Van Vloten et al, 1980; Whang-Peng et al, 1982),
including speci®c rearrangements involving 9p21±23 (Berger et al,
1988). The P15 and P16 genes are intricately linked on 9p21 and
encode cyclin-dependent kinase inhibitors, which play a crucial
part in the control of the cell cycle. Inactivation of the P15 and P16
genes is a frequent ®nding in high-grade non-Hodgkin's lymphoma
(Gombart et al, 1995; Heyman et al, 1996), but has also been
detected in a small study of patients with early cutaneous stages of
mycosis fungoides (Peris et al, 1999). We selected markers that were
close to the loci of the P15 and P16 genes for LOH analysis,
including one that is located between the exons of these genes. We
identi®ed LOH on 9p21 in 46% of patients with SeÂzary syndrome
and 16% with mycosis fungoides and allelic loss did not appear to be
related to cutaneous stage. The P15 and P16 genes are frequently
inactivated by hypermethylation of promoter sites, but rarely by
small deletions or point mutations (Herman et al, 1997). Therefore,
rates of LOH may underestimate the true prevalence of inactivation
of these genes and further detailed studies of these genes would be
bene®cial
We did not detect any correlation between allelic loss and
clinical features in mycosis fungoides: there was no signi®cant
difference in the age at diagnosis or number of treatments received
by those with LOH and those without, which suggests that
increasing age and multiple treatments do not predispose patients to
allelic loss. Losses were more prevalent in advanced cutaneous
stages of mycosis fungoides (T3 and T4) than early stage disease;
however, lymph node involvement did not appear to be associated
with an increased rate of LOH occurring in four patients with and
four without LOH. In SeÂzary syndrome all patients have
erythrodermic disease (T4) but we found that those patients with
LOH were more likely to have lymph node involvement (stage
IVA) than those without LOH, all of whom had stage III disease.
In patients with mycosis fungoides the disease-speci®c death rate
was found to be three times higher in those demonstrating LOH
than those without, although this did not reach statistical signi®c-
ance (p = 0.17). It might appear that this ®nding can be explained
by the increased prevalence of LOH in advanced stages of mycosis
fungoides; however, the disease-speci®c death rate was 2.5 times
higher in those with LOH and early stage disease, whereas in
advanced cutaneous disease the disease-speci®c death rate was
similar in those with or without LOH. This suggests that allelic loss
may contribute to a more aggressive phenotype in mycosis
fungoides particularly in early stage disease; however, patient
numbers are small and further studies are required to validate this
observation.
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In SeÂzary syndrome survival data are dif®cult to interpret due to a
shorter follow-up period; however the time from diagnosis was
longer in those without LOH, at 5.6 y compared with those
demonstrating LOH, at 2.5 y. In addition the ®ve patients with
LOH on more than one chromosomal arm had a follow up of only
1.8 y. This trend suggests that allelic loss may be more prevalent in
those patients with SeÂzary syndrome who have a worse prognosis.
LOH studies have been extensively used to allelotype a wide
variety of malignancies, but until now this technique has not been
used in CTCL. This approach provides a sensitive method of
screening chromosomes for regions of allelic loss and the likely sites
of tumor suppressor genes involved in the pathogenesis of mycosis
fungoides and SeÂzary syndrome; however this technique would not
detect gross chromosomal abnormalities such as translocations,
trisomy, or polyploidy, which have been frequently found in
advanced CTCL (Whang-Peng et al, 1982; Berger et al, 1988;
Thangavelu et al, 1997; Karenko et al, 1999). Furthermore, this
method involves the comparison of tumor DNA with a large
dominant clone and normal DNA, which may eliminate patients
with the earliest stages of mycosis fungoides.
Allelic loss on 9p21 and 17p13 was present in almost half the
patients with SeÂzary syndrome, suggesting that tumor suppressor
genes at these loci, namely the P15, P16 (9p21), and P53 (17p13)
genes may be frequently inactivated by LOH in SeÂzary syndrome.
LOH on 10q and 17p was found in advanced stages of mycosis
fungoides suggesting that tumor suppressor genes, such as the
PTEN (10q23.3), Fas (10q24.1), and P53 (17p13.1) genes may be
associated with disease progression in mycosis fungoides, whereas
losses on 1p and 9p were not related to cutaneous stage suggesting
that tumor suppressor genes in these regions, such as the P18
(1p32), TAL1 (1p32), and P16 (9p21) genes might be associated
with early stage mycosis fungoides.
In eight patients with allelic loss DNA with a large dominant
tumor population was available from both plaques and tumors for
comparative LOH analysis: three patients with LOH on 9p21 and
one with loss on 1p demonstrated allelic loss in DNA from both
plaques and tumor lesions. Two patients with LOH on 10q, one
with LOH on 17p, and one with LOH on 1p had losses con®ned to
tumor samples with retention of heterozygosity in DNA from
plaque stage disease. These data support the concept that a tumor
suppressor gene(s) on 9p may be important in early disease, whereas
those on 10q and 17p may play a part in disease progression;
however patient numbers are too small to draw any further
conclusions from these data and speci®c studies of different
cutaneous stages of mycosis fungoides from individual patients,
including microdissection of tumor cells from early stage disease
will be required to substantiate this.
This study has identi®ed several consistent regions of chromo-
somal loss involved in the pathogenesis of mycosis fungoides and
SeÂzary syndrome. This provides the basis for further more detailed
physical mapping studies and a rational approach for targeting
analysis of speci®c tumor suppressor genes in CTCL.
REFERENCES
Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD: Mantle cell
lymphomas: a clinicopathological study of 80 cases. Blood 89:2067±2078, 1997
Baeg G-H, Matsumine A, Kuroda T, Bhattacharjee RN, Miyashiro I, Toyoshima K,
Akiyama T: The tumour suppressor gene product APC blocks cell cycle
progression from G0/G1 to S phase. EMBO J 14:5618±5625, 1995
Baens M, Wlodarska I, Corveleyn A, Hoornaert I, Hagemeijer A, Marynen P: A
physical, transcript, and deletion map of chromosome region 12p12.3 ¯anked
by ETV6 and CDKN1B: Hypermethylation of the LRP6 CpG island in two
leukemia patients with hemizygous del (12p). Genomics 56:40±50, 1999
Barbieri D, Spanedda R, Castoldi GL: Involvement of chromosome 12 and 14 in the
cutaneous stage of mycosis fungoides: cytogenetic evidence for a multistep
pathogenesis of the disease. Cancer Genet Cytogenet 20:287±292, 1986
Beckmann MW, Picard F, An HX, et al: Clinical impact of detection of loss of
heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J
Cancer 73:1220±1226, 1996
Berger R, Baranger L, Bernheimm A, Valensi F, Flandrin G: Cytogenetics of T-cell
malignant lymphoma: Report of 17 cases and review of the chromosomal
breakpoints. Cancer Genet Cytogenet 36:123±130, 1988
Beylot-Barry M, Groppi A, Vergier B, Pulford K, Merlio JP: Characterization of
t(2;5) reciprocal transcripts and genomic break points in CD30+ve cutaneous
lymphoproliferations. Blood 91:4668±4676, 1998
Bollag G, Clapp DW, Shih S, et al: Loss of NF1 results in activation of the Ras
signaling pathway and leads to aberrant growth in haematopoietic cells. Nat
Genet 12:144±148, 1996
Brito-Babpulle V, Maljaie SH, Matutes E, Hedges M, Yuille M, Catovsky D:
Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic
leukaemia: a cytogenetic analysis with in situ hybridization. Br J Haematol
96:724±732, 1997
Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F: Frequent loss
of heterozygosity on chromosome 10q in muscle-invasive transitional cell
carcinomas. Oncogene 14:3059±3066, 1997
Cave H, Guidal C, Elia J, Vilmer E, Grandchamp BL: A low rate of loss of
heterozygosity is found at many different loci in childhood B-lineage acute
lymphocytic leukaemia. Leukaemia 10:1486±1491, 1996
Cerroni L, Volkenandt M, Reiger E, Soyer P, Kerl H: Bcl-2 protein expression and
correlation with the inter-chromosomal 14; 18 translocation in cutaneous
lymphoma and pseudolymphoma. J Invest Dermatol 102:231±235, 1994
Chen H, Antonarakis SE: Localization of a human homolog of the mouse Tiam-1
gene to chromosome 21q22.1. Genomics 30:123±127, 1995
Chiou S, Rao L, White E: Bcl-2 blocks p53 dependent apoptosis. Mol Cell Biol
14:2556±2563, 1994
DeCoteau J, Butmarc J, Kinney M, Kadin ME: The t(2;5) chromosomal translocation
is not a common feature of primary cutaneous CD30+ lymphoproliferative
disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
Blood 87:3437±3441, 1996
Edelson RL, Berger CL, Raafat J, Warburton D: Karyotype studies of cutaneous T-
cell lymphoma: Evidence for clonal origin. J Invest Dermatol 73:548±550, 1979
Fu TJ, Peng J, Lee G, Price DH, Flores O: Cyclin K functions as a CDK9 regulatory
subunit and participates in RNA polymerase II transcription. J Biol Chem
274:34527±34530, 1999
Futreal PA, Barrett JC, Wiseman RW: An Alu polymorphism intragenic to the TP53
gene. Nucleic Acids Res 19:6977, 1991
Gaidano G, Ballerini P, Gong JZ, et al: p53 mutations in human lymphoid
malignancies: association with Burkitt lymphoma and chronic lymphocytic
leukaemia. Proc Natl Acad Sci USA 88:5413±5417, 1991
Gombart AF, Morosetti R, Miller CW, Said JW, Koef¯er HP: Deletions of the
cyclin-dependant inhibitor genes p16 and p15 in non-Hodgkin's lymphoma.
Blood 86:1534±1539, 1995
Gyapay G, Morissette J, Vignal A, et al: The 1993±4 Genethon Human Genetic
Linkage Map. Nat Genet 7:246±249, 1994
Hatta Y, Yamada Y, Tomonaga M, et al: Allelotyping analysis of adult T-cell
leukaemia. Blood 92:2113±2117, 1998
Hatta Y, Spirin K, Tasaka T, et al: Analysis of p18 (INK4C) in adult T-cell leukaemia
and non-Hodgkin's lymphoma. Br J Haematol 99:665±667, 1997
Hatta Y, Yamada Y, Tomonaga M, Miyoshi I, Said JW, Koef¯er HP: Detailed
mapping of the long arm of chromosome 6 adult T-cell leukaemia. Blood
93:613±616, 1999
Herman JG, Civin CI, Issa J-PJ, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns
of inactivation of p15 (INK4B) and p16 (INK4A) characterize the major types
of hematological malignancies. Cancer Res 57:837±841, 1997
Heyman M, Rasool O, Borgonov-Brandter L, et al: Prognostic importance of
p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic
leukemia. J Clin Oncol 14:1512±1520, 1996
Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial
melanoma. Nat Genet 8:15±21, 1994
Indraccolo S, Minuzzo S, Nicoletti L et al: Mutator phenotype in human
hematopoietic neoplasms. and its association with deletions disabling DNA
repair genes and bcl-2 rearrangements. Blood 94:2424±2432, 1999
Janssen JW, Ludwig WD, Sterry W, Bartram CR: SIL-TAL1 deletion in T-cell acute
lymphoblastic leukemia. Leukemia 7:1204±1210, 1993
Johnson GA, Dewald GW, Strand WR, Winkelmann RK: Chromosome studies in
17 patients with SeÂzary syndrome. Cancer 55:2426±2433, 1985
Karenko L, Hyytinen E, Sarna S, Ranki A: Chromosomal abnormalities in cutaneous
T-cell lymphoma and in its premalignant conditions as detected by G-banding
and interphase cytogenetic methods. J Invest Dermatol 108:22±29, 1997
Karenko L, Kahkonen M, Hyytinen E, Lindlof M, Ranki A: Notable losses at speci®c
regions of chromosome 10q and 13q in the SeÂzary syndrome detected by
comparative genomic hybridization. J Invest Dermatol 112:392±395, 1999
Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/
lymphomas due to hypermethylation. Blood 94:1113±1120, 1999
Komada Y, Inaba H, Zhou Y-W, Zhang X-L, Tanaka S, Azuma E, Sakurai M:
mRNA expression of Fas receptor (CD95) -associated proteins (Fas-associated
phosphatase-1/FAP-1, Fas-associating protein with death domain/FADD, and
receptor-interacting protein/RIP) in human leukaemia/lymphoma cell lines.
Br J Haematol 99:325±330, 1997
Kurzrock R, Gutterman JU, Topless M: The molecular genetics of Philadelphia
chromosome-positive leukaemias. N Engl J Med 319:990±998, 1988
Lagneaux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P: Heterogenous
response of B lymphocytes to transforming growth factor-beta in B-cell
chronic lymphocytic leukaemia: Correlation with the expression of TGF-beta
receptors. Br J Haematol 97:612±620, 1997
Lamberg SI, Green SB, Byar DP, et al: Clinical staging for cutaneous T-cell
lymphoma. Ann Intern Med 100:187±192, 1984
Lauritzen A, Vejlsgaard G, Hou-Jensen K, Ralfkier E: p53 protein expression in
cutaneous T-cell lymphomas. Br J Dermatol 133:32±36, 1995
Limon J, Nedoszytko B, Brozek I, Hellmann A, Zajaczek S, Lubinski J, Mrozek K:
VOL. 117, NO. 3 SEPTEMBER 2001 LOH IN MYCOSIS FUNGOIDES AND SEÂZARY SYNDROME 669
Chromosome aberrations, spontaneous SCE and growth kinetics in PHA-
stimulated lymphocytes in 5 cases of SeÂzary syndrome. Cancer Genet Cytogenet
83:75±81, 1995
Lowsky R, DeCoteau JF, Reitmair AH, et al: Defects of the mismatch repair gene
MSH2 are implicated in the development of murine and human lymphoblastic
lymphomas and are associated with the aberrant expression of rhombotin-2 and
Tal-1. Blood 89:2276±2282, 1997
Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-beta receptor
in colon cancer cells with microsatellite instability. Science 268:1336±1338,
1995
Marks D, Vonderheid E, Kurz B, et al: Analysis of p53 and mdm-2 expression in 18
patients with SeÂzary syndrome. Br J Haematol 92:890±899, 1996
Marrogi AJ, Khan MA, Vonderheid EC, Wood GS, McBurney E: p53 tumour
suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study
of 12 cases. J Cut Pathol, 1999 26:369±378
McGregor J, Dublin E, Levison D, MacDonald DM, Smith NP, Whittaker S: p53
immunoreactivity is uncommon in primary cutaneous lymphoma. Br J Dermatol
132:353±358, 1995
McGregor JM, Crook T, Fraser-Andrews EA, Rozycka M, Crossland S, Whittaker
SJ: Spectrum of p53 gene mutations suggests a possible role for ultraviolet
radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest
Dermatol 112:317±321, 1999
Merup M, Moreno TC, Heyman M, et al: 6q deletions in acute lymphoblastic
leukemia and non-Hodgkin's lymphomas. Blood 91:3397±4000, 1998
Molenaar JJ, Gerard B, Chambon-Pautas C, Cave H, Duval M, Vilmer E,
Grandchamp B: Microsatellite instability and frameshift mutations in BAX and
transforming growth factor-beta RII genes are very uncommon in acute
lymphoblastic leukemia in vivo but not in cell lines. Blood 92:230±233, 1998
Mori N, Morosetti R, Lee S, et al: Allelotype analysis in the evolution of chronic
myeloid leukaemia. Blood 90:2010±2014, 1997
Mori N, Morosetti R, Spira S, et al: Chromosome band 1p36 contains a putative
tumor suppressor gene important in the evolution of chronic myelocytic
leukemia. Blood 92:3405±3409, 1998
Nakahara Y, Nagai H, Kinoshita, Uchida T, Hatana S, Saito H: Mutational analysis
of the PTEN gene in non-Hodgkin's lymphoma. Leukaemia 12:1277±1281,
1998
Navas IC, Oritz-Romero PL, Villuendas R, et al: p16 gene alterations are frequent in
lesions of mycosis fungoides. Am J Pathol 156:1565±1572, 2000
Newton CR, Graham A: Fingerprinting. In: Introduction to Biotechniques. BIOS
Scienti®c Publishers, 1997.
Nowell PC, Finan JB, Vonderheid EC: Clonal characteristics of cutaneous T-cell
lymphomas: cytogenetic evidence from blood, lymph nodes and skin. J Invest
Dermatol 78:69±75, 1982
Nowell PC, Vonderheid EC, Besa E, Hoxie JA, Moreau L, Finan JB: The most
common chromosome change in 86 chronic B cell or T cell tumours: a 14q32
translocation. Cancer Genet Cytogenet 19:219±227, 1986
Of®t K, Parsa NZ, Gaidano G, et al: 6q Deletions de®ne distinct clinico-pathologic
subsets of non-Hodgkin's lymphoma. Blood 82:2157±2162, 1993
Payne SJ: Laboratory methods for the detection of mutations and polymorphisms. In:
Taylor CR, eds. Microsatellite Analysis. CRC Press, 1997
Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ: Allelic
loss of sequences from the long arm of chromosome 10 and replication errors in
endometrial carcinomas. Cancer Res 55:1922±1926, 1995
Peris K, Stanta G, Fargnoli C, Bonin S, Felli A, Amantea A, Chimenti S: Reduced
expression of CDKN2a/p16 in mycosis fungoides. Arch Dermatol Res 291:207±
211, 1999
Perotti D, Pettenella F, Luksch R, et al: Molecular analysis of 1p32 genetic
involvement in pediatric T-cell non- Hodgkin's lymphoma. Haematologica 84:,
110±113, 1999
Pescarmona E, Pignoloni P, Santangelo C, et al: Expression of p53 and
retinoblastoma gene in high grade nodal peripheral T-cell lymphomas. J
Pathol 188:400±406, 1999
Ragnarsson G, Eiriksdottir G, Johannsdottir JTh et al: Loss of heterozygosity at
chromosome 1p in different solid human tumours: Association with survival. Br
J Cancer 79:1468±1474, 1999
Rasmussen UB, Wolf C, Mattei M-G, et al: Identi®cation of a new interferon-alpha-
inducible gene (p27) on human chromosome 14q32 and its expression in breast
carcinoma. Cancer Res 53:4096±4101, 1993
Russell-Jones R, Whittaker S: TCR gene analysis in the diagnosis of SeÂzary
syndrome. J Am Acad Dermatol, 1999 41:254±259
Sarma V, Wolf FW, Marks RM, Shows TB, Dixit VM: Cloning of a novel tumor
necrosis factor-alpha-inducible primary response gene that is differentially
expressed in development and capillary tube-like formation in vitro. J Immunol
148:3302±3312, 1992
Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ: Loss of heterozygosity on
10q and MSI in primary cutaneous T-cell lymphoma is found in advanced
disease and may be associated with homozygous deletion of PTEN. Blood
95:2937±2942, 2000
Shapiro PE, Warburton D, Berger CL, Edelson RL: Clonal chromosomal
abnormalities in cutaneous T-cell lymphoma. Cancer Genet Cytogenet 28:267±
276, 1987
Sole F, Woessner S, Vallespi T, et al: Cytogenetic studies in 5 patients with SeÂzary
syndrome. Cancer Genet Cytogenet 36:123±130, 1988
Takeuchi S, Bartram CR, Wada M, et al: Allelotyping analysis of childhood acute
lymphoplastic leukaemia. Cancer Res 55:5377±5382, 1995
Takeuchi S, Koike M, Park S, et al: The ATM gene and susceptibility to childhood
T-cell acute lymphoblastic leukemia. Br J Haematol 103:536±538, 1998
Thangavelu M, Finn WG, Yelavarthi KK, et al: Recurring structural chromosomal
abnormalities in peripheral blood lymphocytes of patients with mycosis
fungoides/SeÂzary syndrome. Blood 89:3371±3377, 1997
Van Vloten WA, Pet EA, Geraedts JPM: Chromosome studies in mycosis fungoides.
Br J Dermatol 102:507±513, 1980
Villuendas R, Pezzella F, Gatter K, et al: p21 (WAF1/CIP1) and MDM2 expression
in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+,
MDM2-, p21- immunophenotype associated with missense p53 mutations. J
Pathol 181:51±61, 1997
Wang SI, Puc J, Li J, Bruce N, Cairns P, Sidransky D, Parsons R: Somatic mutations
of PTEN in glioblastoma multiforme. Cancer Res 57:4183±4186, 1997
Weinstock MA, Gardstein B: Twenty-year trends in the reported incidence of
mycosis fungoides and associated mortality. Am J Public Health 89:1240±1244,
1999
Weiss LM, Warnke RA, Sklar J, Cleary ML: Molecular analysis of the t(14;18)
chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185±
1189, 1987
Whang-Peng J, Bunn P, Knutsen T, Schechter GP, Gazdar AF, Mathews MJ, Minna
JD: Cytogenetic abnormalities in patients with cutaneous T-cell lymphoma.
Cancer Treat Rep 63:575±580, 1979
Whang-Peng J, Bunn P, Knutsen T, Mathews MJ, Schechter GP, Minna JD: Clinical
implications of cytogenetic studies in cutaneous T-cell lymphoma. Cancer
50:1539±1553, 1982
Whittaker SJ, Smith NP, Russell-Jones R, Luzzatto L: Analysis of beta, gamma and
delta TCR genes in mycosis fungoides and SeÂzary syndrome. Cancer 68:1572±
1582, 1991
Willemze R, Kerl H, Sterry W, et al: EORTC classi®cation for primary cutaneous
lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the
European Organization for Research and Treatment of Cancer. Blood 90:354±
371, 1997
Zackheim HS, Amin S, Kashani-Sabet M, McMillan A: Prognosis in cutaneous T-
cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad
Dermatol 40:418±425, 1999
Zhou XP, Hoang JM, Cottu P, Thomas G, Hamelin R: Allelic pro®les of
mononucleotide repeat microsatellites in control individuals and in colorectal
tumours with and without replication errors. Oncogene 15:1713±1718, 1997
670 SCARISBRICK ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
